Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Waldenström’s Macroglobulinemia

Explore the latest updates and expert interviews

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

VJHemOnc presents the Waldenström’s Macroglobulinemia Channel

Welcome to the Waldenström’s Macroglobulinemia Channel, bringing you the latest data from world-renowned experts on Waldenström’s macroglobulinemia through exclusive interviews, podcasts, roundtable discussions, and more.

Explore the latest advances, such as rituximab and proteasome inhibitor-based therapies that have demonstrated efficacy in symptom management, and targeted therapies that are increasingly playing a role in tailoring treatment options, directly from leading experts on the Waldenström’s Macroglobulinemia Channel.

Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes 2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Phase I trial of LY4152199, a BAFF-R-targeting bispecific, in previously treated B-cell malignancies 0:56
Phase I trial of LY4152199, a BAFF-R-targeting bispecific, in previously treated B-cell malignancies
Krish Patel • 8 Dec 2025
Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM 0:51
Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM
Meletios Dimopoulos • 7 Dec 2025
Updated data on bexobrutideg in Waldenström’s macroglobulinemia: an ongoing Phase Ia/b trial 2:11
Updated data on bexobrutideg in Waldenström’s macroglobulinemia: an ongoing Phase Ia/b trial
Nirav Niranjan Shah • 6 Dec 2025
Long-term follow-up of pirtobrutinib therapy in Waldenström’s macroglobulinemia: the BRUIN trial 1:14
Long-term follow-up of pirtobrutinib therapy in Waldenström’s macroglobulinemia: the BRUIN trial
Chan Yoon Cheah • 5 Dec 2025
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials 14:48
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
Alexey Danilov et al. • 28 Sep 2025
Therapeutic goals in Waldenström’s macroglobulinemia: achieving disease control 1:06
Therapeutic goals in Waldenström’s macroglobulinemia: achieving disease control
Anna Maria Frustaci • 20 Jun 2025
The role of therapeutic plasma exchange in managing plasma cell disorders 7:59
The role of therapeutic plasma exchange in managing plasma cell disorders
Danai Dima • 24 Jun 2025
Updates from the BRAWM trial: bendamustine, rituximab and acalabrutinib in patients with WM 1:59
Updates from the BRAWM trial: bendamustine, rituximab and acalabrutinib in patients with WM
Neil Berinstein • 19 Jun 2025
Sonrotoclax monotherapy in R/R Waldenström’s macroglobulinemia: initiation of BGB-11417-203 0:51
Sonrotoclax monotherapy in R/R Waldenström’s macroglobulinemia: initiation of BGB-11417-203
Chan Yoon Cheah • 14 Jun 2025
The safety of bendamustine-rituximab and acalabrutinib in frontline Waldenström’s macroglobulinemia 1:25
The safety of bendamustine-rituximab and acalabrutinib in frontline Waldenström’s macroglobulinemia
Neil Berinstein • 19 Jun 2025
Emerging agents for Waldenström’s macroglobulinemia: non-covalent BTKis, BCL2 antagonists, & more 1:11
Emerging agents for Waldenström’s macroglobulinemia: non-covalent BTKis, BCL2 antagonists, & more
Neil Berinstein • 19 Jun 2025
Salvage treatment strategies after covalent BTKis in Waldenström’s macroglobulinemia 1:47
Salvage treatment strategies after covalent BTKis in Waldenström’s macroglobulinemia
Anna Maria Frustaci • 20 Jun 2025
Updated data on the safety and efficacy of BGB-16673 in R/R Waldenström’s macroglobulinemia 1:38
Updated data on the safety and efficacy of BGB-16673 in R/R Waldenström’s macroglobulinemia
Anna Maria Frustaci • 20 Jun 2025

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals